Breast Cancer Treatment in China: What Subtype Changes, What a One-Cut Package Doesn't
Breast cancer care in China follows subtype, not a shopping list of hospitals. IARC GLOBOCAN 2024: 375,808 new cases. HR-positive, HER2-positive and triple-negative disease are different protocols. Drugs usually move the bill more than the operation. Send ER/PR/HER2. About 24 hours. No obligation to book.
Average reply: 24 hoursNo obligation to book
Subtype firstHR HER2 TNBC
375,808 casesIARC 2024
Drugs move the billmore than the operation
Quick answer
Breast cancer care in China follows subtype, not a shopping list of hospitals. IARC GLOBOCAN 2024: 375,808 new cases (7.3%). HR-positive, HER2-positive and triple-negative disease are different protocols. Conserving surgery plus radiation is ordinary at high-volume public units when staging allows. Drugs usually move the bill more than the operation. CAR-T is not standard breast-cancer care. Send ER/PR/HER2. About 24 hours. No obligation to book.
Breast: subtype picks the protocol
HR-positive
Endocrine backbone, CDK4/6 in indicated lines. Months of drug, not a two-week tour.
HER2-positive
Anti-HER2 agents usually dwarf the operating-room line. Names must be on the quote.
Triple-negative
Chemo +/- IO when indicated. Conserving surgery still needs a radiation story.
| Question | Usual comparison | Cost note |
|---|---|---|
| Conserving surgery + radiation | Fudan, CAMS/NCC, PKU Cancer, SYSUCC | OR + stay + RT calendar — not one SKU |
| HER2 / CDK4/6 / TNBC-IO drugs | Same public breast units | Often the largest line — list names |
| Selected left-sided / re-irradiation proton | SPHIC / Ruijin if geometry fits | ~USD 20-35k course band if accepted |
| Breast CAR-T ad | Trial claim until named | Do not use blood-cancer CAR-T prices |
What actually changes the plan
📋
Subtype before a hospital name
ER/PR, HER2, grade, nodes. TNBC, HER2+ and HR+ do not share a brochure.
🏥
Breast unit, not a ranking
Fudan, CAMS/NCC, PKU Cancer, SYSUCC. Conserving surgery needs a radiation plan in the same story.
✈️
Drugs outlast the flight
HER2 agents, CDK4/6, IO in selected TNBC. The medical PDF that hides drug names is not a quote.
What this page helps you decide
✅
Conserving vs mastectomy labelled
We do not sell reconstruction as proof of a better oncology plan.
💬
Drug drivers on the table
The expensive line is often months of targeted therapy, not the operating room.
🌍
Same hospital map as the hub
No second mythology. Fuda is compared, not assumed.
Evidence table
IARC breast burden, NCCN/CSCO subtype maps, pyrotinib as a China-origin HER2 TKI.
| Source | What it says | Relevance to patients |
|---|---|---|
| IARC GLOBOCAN China (2024) | 375,808 new cases; ~73,030 deaths | Volume sits in public cancer hospitals. |
| NCCN / CSCO breast maps (current) | Subtype-directed endocrine, anti-HER2, TNBC pathways | No ER/PR/HER2, no plan. |
| Pyrotinib CSCO listing (current) | China-origin HER2 TKI for selected HER2-positive disease | A drug class, not a hospital brand. |
Who this page is for
Early-stage patients seeking conserving surgery
Need a unit that will say yes or no after imaging, with radiation in the same plan.
HER2+ or TNBC needing systemic sequencing
Need drug names and line of therapy, not a two-week package.
Metastatic patients after several lines
Need honest control goals and a centre that will read the full chemo history.
What you can actually book
Fudan University Shanghai Cancer Center, CAMS/NCC, PKU Cancer, SYSUCC. We compare any private slogan with one of those public breast units. Related: cancer hub, cost.
What moves the cost
Breast file review
No charge to start
Subtype split • Surgery/radiation note • Centre shortlist • Drug-driver warning
Coordinated trip
Quoted after records
Hospital matching • Itemised drivers • Visa • Interpreter
These are routing steps, not a hospital package SKU. Published procedure examples stay in the evidence/cost sections only when a source exists. Hospital, drugs, stay, interpreter and travel are quoted separately after records.
What happens next
01
Send receptors and staging
Plus prior surgery or systemic therapy. Missing HER2 status blocks a real shortlist.
02
Pick the sequence
Neoadjuvant vs upfront surgery, radiation need, targeted/endocrine plan.
03
Travel after the unit accepts
Invitation, visa, interpreter. Reconstruction, if wanted, is a separate consent.
Request a preliminary case review
Tell us the basics of your case. When you submit, WhatsApp will open with the information you entered so you can review it before sending. This is a preliminary routing request, not a diagnosis, treatment acceptance, trial enrollment, visa decision, or medical advice.
Frequently asked questions
How much is breast cancer treatment in China?
Drugs usually outrun the operation in metastatic and many adjuvant settings. We itemise after subtype. There is no one-cut package price.
Can I have breast-conserving surgery in China?
Yes, at high-volume public units when anatomy and staging allow. Mastectomy is not an upgrade.
What is pyrotinib?
A China-origin HER2 TKI on CSCO maps for selected HER2-positive disease. The file still needs confirmed HER2 status.
Is CAR-T used for breast cancer?
Not as standard of care.
Which hospitals?
Fudan Shanghai Cancer Center, CAMS/NCC, PKU Cancer, SYSUCC.
What records should I send?
ER/PR/HER2 (IHC plus FISH when 2+), Ki-67, imaging, operative notes, BRCA if done, prior lines.
Is Fuda the default breast hospital?
No.
Do you promise a reconstruction result?
No. Average reply about 24 hours. No obligation to book.
Do I pay before you read the file?
No. Payment required before a file review is a red flag. Average reply about 24 hours. No obligation to book.
How fast do you reply?
About 24 hours. We label the file as labelled care, trial, or marketing. No obligation to book.
Red flags in offers
A one-cut mastectomy package, or Fuda as the breast campus. Reconstruction sold as an “upgrade.” Ordinary endocrine therapy that could be prescribed at home, wrapped as a China trip.
Quote without ER/PR/HER2.
One package for HR+, HER2+ and TNBC.
CAR-T or stem cells as breast-cancer care.
Pay before pathology is read.
Sources
IARC GLOBOCAN 2024 China fact sheet.
NCCN and CSCO breast-cancer maps; pyrotinib as a China-origin HER2 TKI on domestic lists.
Public descriptions of FUSCC, CAMS/NCC, PKU Cancer, SYSUCC.
Freshness label on this page: 2026-08-15
Medical note
A treating oncologist should review imaging and pathology before you travel. This page is matching information, not a treatment recommendation.